[Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)].
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
Kensuke
K
Kumamoto
Keiichiro
K
Ishibashi
Hideyuki
H
Ishida
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics*; D004720:Endonucleases / Q000235:genetics*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000032:analysis; D027361:Organic Anion Transporters / Q000235:genetics; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000032:analysis*; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
D004268:DNA-Binding Proteins; D004720:Endonucleases; D005472:Fluorouracil; D002955:Leucovorin; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D027361:Organic Anion Transporters; D009944:Organoplatinum Compounds; D013940:Thymidylate Synthase; D051759:Xeroderma Pigmentosum Group D Protein; C487009:SLCO6A1 protein, human; C071447:ERCC1 protein, human